Daclatasvir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Daclatasvir
Daclatasvir.svg
Identifiers
CAS number 1009119-64-5 YesY
ChemSpider 24609522
ChEMBL CHEMBL2023898, CHEMBL2303621
Jmol-3D images Image 1
Properties
Molecular formula C40H50N8O6
Molar mass 738.88 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Daclatasvir (USAN[1]) (formerly BMS-790052) is an experimental drug candidate for the treatment of hepatitis C (HCV). It is being developed by Bristol-Myers Squibb.

Daclatasvir inhibits the HCV nonstructural protein NS5A.[2][3] Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.[4]

Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin,[5] as well as with other direct-acting antiviral agents including asunaprevir[6][7][8][9] and sofosbuvir.[10][11]

References[edit]

  1. ^ Statement on a Nonproprietary Name Adopted by the USAN Council
  2. ^ Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G. (2010). "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect". Nature 465 (7294): 96–100. doi:10.1038/nature08960. PMID 20410884. 
  3. ^ Bell, Thomas W. (2010). "Drugs for hepatitis C: unlocking a new mechanism of action". ChemMedChem 5 (10): 1663–1665. doi:10.1002/cmdc.201000334. PMID 20821796. 
  4. ^ Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Guedj, J et al. Proceedings of the National Academy of Sciences. February 19, 2013.
  5. ^ AASLD: Daclatasvir with Pegylated Interferon/Ribavirin Produces High Rates of HCV Suppression. Highleyman, L. HIVandHepatitis.com. 6 December 2011.
  6. ^ Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. Lok, A et al. New England Journal of Medicine. 366(3):216-224. January 19, 2012.
  7. ^ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. Apr 19, 2012. 
  8. ^ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders. Highleyman, L. HIVandHepatitis.com. 8 November 2011.
  9. ^ High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype. Alcorn, K. Aidsmap.com. 12 November 2012.
  10. ^ AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3. Highleyman, L. HIVandHepatitis.com. 15 November 2012.
  11. ^ Mark Sulkowski et al. (January 16, 2014). "Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection". New England Journal of Medicine.